Head and Neck Squamous Cell Cancer
Conditions
Brief summary
The purpose of this study is to assess the effect of metformin in tumor metabolism in patients with head and neck cancer by evaluating metformin's ability to decrease TOMM20 expression in squamous carcinoma cells and decrease MCT4 expression in fibroblasts.
Interventions
DRUGMetformin
Sponsors
Sidney Kimmel Cancer Center at Thomas Jefferson University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of head and neck cancer biopsy proven, and who have a scheduled appointment for definitive resection of the tumor at TJUH * Age ≥ 18 years of age and ≤80 years old. * Newly diagnosed with HNSCC cancer. * No prior therapy for HNSCC cancer is permitted for enrollment in the trial. * All subjects must be able to comprehend and sign a written informed consent document.
Exclusion criteria
* Pregnant or may become pregnant during metformin administration. * On metformin for any reason during the preceding 4 weeks. * Diabetic patients are eligible if they are not taking metformin, insulin or sulfonylureas. * Received iodinated contrast dye less than 48 hours prior to screening meet a temporary
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in TOMM20 and MCT4 expression from tumor cells from date of biopsy and date of surgery | date of biopsy and date of surgery (9-28 days) |
Countries
United States
Outcome results
None listed